BR112022003282A2 - Glicovariantes de igm - Google Patents

Glicovariantes de igm

Info

Publication number
BR112022003282A2
BR112022003282A2 BR112022003282A BR112022003282A BR112022003282A2 BR 112022003282 A2 BR112022003282 A2 BR 112022003282A2 BR 112022003282 A BR112022003282 A BR 112022003282A BR 112022003282 A BR112022003282 A BR 112022003282A BR 112022003282 A2 BR112022003282 A2 BR 112022003282A2
Authority
BR
Brazil
Prior art keywords
igm
heavy chain
variant
derived
glycovariants
Prior art date
Application number
BR112022003282A
Other languages
English (en)
Inventor
Bruce Keyt
Dean Ng
Ramesh Baliga
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of BR112022003282A2 publication Critical patent/BR112022003282A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

glicovariantes de igm referência cruzada a pedidos relacionados. esta divulgação fornece uma molécula de ligação derivada de igm isolada, por exemplo, um anticorpo igm, anticorpo semelhante a igm ou outra molécula de ligação derivada de igm, incluindo pelo menos uma cadeia pesada derivada da igm variante, onde a pelo menos uma cadeia pesada derivada da igm variante inclui uma região constante de cadeia pesada da igm variante associada a um domínio de ligação que se liga especificamente a um alvo, onde pelo menos um motivo de gli-cosilação (n)-ligado de asparagina da região constante de cadeia pesada da igm variante é mutado para evitar a glicosilação nesse motivo, e/ou pelo menos um mo-tivo de glicosilação n-ligado é introduzido na cadeia pesada da igm variante.
BR112022003282A 2019-08-23 2020-08-21 Glicovariantes de igm BR112022003282A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962891263P 2019-08-23 2019-08-23
PCT/US2020/047495 WO2021041250A1 (en) 2019-08-23 2020-08-21 Igm glycovariants

Publications (1)

Publication Number Publication Date
BR112022003282A2 true BR112022003282A2 (pt) 2022-05-24

Family

ID=74684266

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003282A BR112022003282A2 (pt) 2019-08-23 2020-08-21 Glicovariantes de igm

Country Status (11)

Country Link
US (1) US20220306760A1 (pt)
EP (1) EP4017533A4 (pt)
JP (1) JP2022545682A (pt)
KR (1) KR20220050166A (pt)
CN (1) CN114269380A (pt)
AU (1) AU2020337333A1 (pt)
BR (1) BR112022003282A2 (pt)
CA (1) CA3149350A1 (pt)
IL (1) IL290253A (pt)
MX (1) MX2022002239A (pt)
WO (1) WO2021041250A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3126383T3 (en) 2014-04-03 2019-04-01 Igm Biosciences Inc MODIFIED J-CHAIN
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
IL311039A (en) * 2021-09-17 2024-04-01 Adimab Llc Anti-CD3 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2125894T1 (sl) * 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
EP2496600A1 (en) * 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
AU2016329197B2 (en) * 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2017106462A1 (en) * 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
WO2018136825A1 (en) * 2017-01-19 2018-07-26 Cedars-Sinai Medical Center Highly multiplexed and mass spectrometry based methods to measuring 72 human proteins
WO2018175752A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies

Also Published As

Publication number Publication date
MX2022002239A (es) 2022-03-22
EP4017533A1 (en) 2022-06-29
AU2020337333A1 (en) 2022-03-03
CA3149350A1 (en) 2021-03-04
US20220306760A1 (en) 2022-09-29
KR20220050166A (ko) 2022-04-22
JP2022545682A (ja) 2022-10-28
WO2021041250A1 (en) 2021-03-04
IL290253A (en) 2022-04-01
CN114269380A (zh) 2022-04-01
EP4017533A4 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
BR112022003282A2 (pt) Glicovariantes de igm
BR112017026704A2 (pt) uso
BR112017025332A2 (pt) anticorpos específicos de receptor de célula t
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
BR112022013545A2 (pt) Anticorpos anti-tigit e método de uso
BR112018013677A2 (pt) proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
BR112017014308A2 (pt) anticorpos biespecíficos contra calicreína plasmática e fator xii
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112022011669A2 (pt) Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica
BR112016026299A2 (pt) molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112018072389A2 (pt) anticorpos que reconhecem tau
BR112021016947A2 (pt) Anticorpos que reconhecem tau
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
CL2012002433A1 (es) Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
CL2019000658A1 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo.
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
BR112021013397A2 (pt) Anticorpos anti-tigit
BR112019011564A2 (pt) anticorpos bivalentes mascarados por hélices superenroladas
BR112017017142A2 (pt) métodos e composições para redução de produtos de amplificação não específicos
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
BR112018003494A2 (pt) anticorpo anti-epha4
NI201900086A (es) Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo.
BR112019008225A2 (pt) spray de aerossol contendo espécies de bactérias viáveis